Sintx Technologies (SINT) Cash from Financing Activities (2013 - 2026)
Sintx Technologies' (SINT) quarterly Cash from Financing Activities came in at $247000.0 in Q1 2026, down 94.21% year-on-year from $4.3 million in Q1 2025, and down 10.51% quarter-over-quarter from $276000.0 in Q4 2025.
Sintx Technologies (SINT) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Sintx Technologies' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $247000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 94.21% year-over-year to $247000.0 in Q1 2026; TTM through Mar 2026 was $4.2 million, a 47.95% decrease from a year earlier, with the FY2025 full-year figure at $8.2 million, down 9.83% from the prior year.
- Cash from Financing Activities slipped to $247000.0 in Q1 2026 per SINT's latest filing, from $276000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $11.5 million in Q1 2023 and bottomed at -$123000.0 in Q2 2025.
- The 5-year median for Cash from Financing Activities is $1.0 million (2024), against an average of $2.5 million.
- Across the five-year window, Cash from Financing Activities jumped 96025.0% in 2022 and plunged 132.8% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $3.8 million in 2022, then tumbled by 91.91% to $311000.0 in 2023, then plunged by 132.8% to -$102000.0 in 2024, then surged by 370.59% to $276000.0 in 2025, then dropped by 10.51% to $247000.0 in 2026.
- Per Business Quant, the three latest SINT Cash from Financing Activities figures stand at $247000.0 (Q1 2026), $276000.0 (Q4 2025), and $3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Sintx Technologies | 17,274.80 | -1.87 Mn | 144,000.00 | 247,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 247,000.00 |
| Mar 31, 2026 | 247,000.00 |
| Dec 31, 2025 | 276,000.00 |
| Dec 31, 2025 | 276,000.00 |
| Sep 30, 2025 | 3.78 Mn |
| Sep 30, 2025 | 3.78 Mn |
| Jun 30, 2025 | -123,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.27 Mn |
| Dec 31, 2024 | -102,000.00 |
| Dec 31, 2024 | -102,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 5.33 Mn |
| Mar 31, 2024 | 5.33 Mn |
| Dec 31, 2023 | 311,000.00 |
| Dec 31, 2023 | 311,000.00 |